全文获取类型
收费全文 | 7024篇 |
免费 | 351篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 111篇 |
妇产科学 | 137篇 |
基础医学 | 799篇 |
口腔科学 | 109篇 |
临床医学 | 542篇 |
内科学 | 1902篇 |
皮肤病学 | 111篇 |
神经病学 | 714篇 |
特种医学 | 381篇 |
外科学 | 1047篇 |
综合类 | 17篇 |
预防医学 | 297篇 |
眼科学 | 53篇 |
药学 | 379篇 |
中国医学 | 13篇 |
肿瘤学 | 770篇 |
出版年
2024年 | 8篇 |
2023年 | 52篇 |
2022年 | 118篇 |
2021年 | 201篇 |
2020年 | 142篇 |
2019年 | 140篇 |
2018年 | 188篇 |
2017年 | 136篇 |
2016年 | 185篇 |
2015年 | 195篇 |
2014年 | 268篇 |
2013年 | 325篇 |
2012年 | 577篇 |
2011年 | 569篇 |
2010年 | 309篇 |
2009年 | 314篇 |
2008年 | 493篇 |
2007年 | 474篇 |
2006年 | 452篇 |
2005年 | 464篇 |
2004年 | 391篇 |
2003年 | 371篇 |
2002年 | 351篇 |
2001年 | 43篇 |
2000年 | 38篇 |
1999年 | 43篇 |
1998年 | 69篇 |
1997年 | 55篇 |
1996年 | 43篇 |
1995年 | 48篇 |
1994年 | 31篇 |
1993年 | 39篇 |
1992年 | 39篇 |
1991年 | 20篇 |
1990年 | 32篇 |
1989年 | 35篇 |
1988年 | 24篇 |
1987年 | 20篇 |
1986年 | 15篇 |
1985年 | 14篇 |
1984年 | 8篇 |
1983年 | 11篇 |
1982年 | 9篇 |
1981年 | 7篇 |
1980年 | 22篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1971年 | 5篇 |
1902年 | 3篇 |
排序方式: 共有7437条查询结果,搜索用时 15 毫秒
61.
Anna Scattone Gilda Caruso Andrea Marzullo Domenico Piscitelli Mattia Gentile Lucia Bonadonna Giuseppe Balducci Maria Cristina Digilio Alessandro Jenkner Francesca Diomedi Camassei Renata Boldrini Pietro Nazzaro Lucio Pollice Gabriella Serio 《Fetal and pediatric pathology》2003,22(4):323-341
Deletion 22q11.2 is a chromosomal abnormality detected in young patients with clinical manifestations of the DiGeorge/velocardiofacial syndrome. Conotruncal heart defects are also associated with del22q11.2. An association of these cardiac malformations with neoplasias has been observed. Our series includes two cases of malignancies, a hepatoblastoma and a renal-cell carcinoma, arising in children with complex cardiac malformations. The aim of the study was to determine if the deletion at 22q11.2 was present and could be responsible for both pathological processes. Del22q11.2 was identified in both cases. Comparative genomic hybridization revealed terminal gains on chromosomes 1q and Xq and terminal loss on 1p in the hepatoblastoma, and gains in 1p, 12q, 16p, 20q, 22q, and whole chromosome 19 and loss of Xq in the renal-cell carcinoma. Our results confirm a common genetic basis for cardiac malformations, and del22q11.2 presents a risk factor for the development of pediatric tumours. 相似文献
62.
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. 总被引:7,自引:0,他引:7
Fabio Pastorino Chiara Brignole Danilo Marimpietri Gabriella Pagnan Adriana Morando Domenico Ribatti Sean C Semple Claudio Gambini Theresa M Allen Mirco Ponzoni 《Clinical cancer research》2003,9(12):4595-4605
PURPOSE: Melanoma is a highly malignant and increasingly common tumor. Because the cure rate of metastatic melanoma by conventional treatment is very low, new therapeutic approaches are needed. We previously reported that coated cationic liposomes (CCL) targeted with a monoclonal antibody against the disialoganglioside (GD(2)) and containing c-myb antisense oligodeoxynucleotides (asODNs) resulted in a selective inhibition of the proliferation of GD(2)-positive neuroblastoma cells in vitro. EXPERIMENTAL DESIGN: Here, we tested the in vivo antitumor effects of this novel antisense liposomal formulation by targeting the c-myc oncogene on melanoma, a neuroectodermal tumor sharing with neuroblastoma the expression of GD(2). RESULTS: Our methods produced GD(2)-targeted liposomes that stably entrapped 90% of added c-myc asODNs. These liposomes showed a selective binding for GD(2)-positive melanoma cells in vitro. Melanoma cell proliferation was inhibited to a greater extent by GD(2)-targeted liposomes containing c-myc asODNs (aGD(2)-CCL-myc-as) than by nontargeted liposomes or free asODNs. The pharmacokinetic results obtained after i.v. injection of [(3)H]-myc-asODNs, free or encapsulated in nontargeted CCLs or GD(2)-targeted CCLs, showed that free c-myc-asODNs were rapidly cleared, with less than 10% of the injected dose remaining in blood at 30 min after injection. c-myc-asODNs encapsulated within either CCL or aGD(2)-CCL demonstrated a more favorable profile in blood, with about 20% of the injected dose of each preparation remaining in vivo at 24 h after injection. In an in vivo melanoma experimental metastatic model, aGD(2)-CCL-myc-as, at a total dose of only 10 mg of asODN per kilogram, significantly inhibited the development of microscopic metastases in the lung compared with animals treated with myc-asODNs, free or entrapped in nontargeted liposomes, or aGD(2)-CCL encapsulating scrambled asODNs (P < 0.01). Moreover, mice bearing established s.c. human melanoma xenografts treated with aGD(2)-CCL-myc-as exhibited significantly reduced tumor growth and increased survival (P < 0.01 versus control mice). The mechanism for the antitumor effects appears to be down-regulation of the expression of the c-myc protein and interruption of c-myc-mediated signaling: induction of p53 and inhibition of Bcl-2 proteins, leading to extensive tumor cell apoptosis. CONCLUSION: These results suggest that inhibition of c-myc proto-oncogene by GD(2)-targeted antisense therapy could provide an effective approach for the treatment of melanoma in an adjuvant setting. 相似文献
63.
Carlo Gambacorti-Passerini Massimo Zucchetti Domenico Russo Roberta Frapolli Magda Verga Silvia Bungaro Lucia Tornaghi Fabio Rossi Pietro Pioltelli Enrico Pogliani Daniele Alberti Gianmarco Corneo Maurizio D'Incalci 《Clinical cancer research》2003,9(2):625-632
PURPOSE: Imatinib (Glivec) is a potent inhibitor of bcr/abl, an oncogenic fusion protein that causes chronic myelogenous leukemia (CML). alpha1 acid glycoprotein (AGP) binds to imatinib with high affinity and inhibits imatinib activity in vitro and in vivo in an animal model. A pharmacokinetics analysis of imatinib was undertaken in CML patients. EXPERIMENTAL DESIGN: Imatinib plasma concentrations were measured in 19 CML patients treated with imatinib (400 or 600 mg/day). Five patients received a concomitant short-term course of clindamycin (CLI). RESULTS: A positive correlation between AGP and imatinib plasma levels was observed. CLI administration decreased imatinib plasma concentrations, evaluated as area under the curve (AUC) and peak concentrations (C(max)). The effects of a bolus of CLI was studied in three patients on imatinib 23 h after the last imatinib dose. Within 5-10 min in three of three cases, CLI caused a decrease in imatinib plasma concentrations of 2.6-, 2.7-, and 4.7-fold, respectively. In vitro experiments using fresh blasts from CML patients showed that AGP, at concentrations observed in the patients, decreased imatinib intracellular concentrations up to 10 times and blocked imatinib activity. The incubation with CLI restored imatinib intracellular concentrations and biological activity. CONCLUSION: AGP exerts significant effects of the pharmacokinetics, plasma concentrations, and intracellular distribution of imatinib in CML patients; these data indicate that plasma imatinib levels represent unreliable indicators of the cellular concentrations of this molecule. 相似文献
64.
Early and late implant failure of submerged versus non‐submerged implant healing: A systematic review,meta‐analysis and trial sequential analysis 下载免费PDF全文
65.
66.
Roberta Cocchiara Giovanna Di Trapani Antonina Azzolina Domenico Geraci 《Journal of immunoassay & immunochemistry》2013,34(4):337-352
Abstract An ELISA assay is described for the measurement of the smIgG. The method is based on the detection of cell-smIgG directly on the same microplate used for the culture. The cells, preincubated at 37°C for one hour, were cultured in the presence of S-ConA and serum-free medium for two days. Using this strategy, the background noise due to non specific adsorbtion of IgG to plastic wells and cytophilic antibodies was eliminated. The cells in the presence of S-ConA and serum-free medium adhered to the plastic wells, and the cell-smIgG were detected using an anti-human IgG covalently linked to alkaline phosphatase or its F(ab')2 fragment. The possibility of measuring the modulation of the expression of the cell-smIgG without any additional manipulation is stressed. 相似文献
67.
Francesco Scolari Elisa Delbarba Domenico Santoro Loreto Gesualdo Antonello Pani Nadia Dallera Laila-Yasmin Mani Marisa Santostefano Sandro Feriozzi Marco Quaglia Giuliano Boscutti Angelo Ferrantelli Carmelita Marcantoni Patrizia Passerini Riccardo Magistroni Federico Alberici Gian Marco Ghiggeri Claudio Ponticelli Pietro Ravani for the RI-CYCLO Investigators 《Journal of the American Society of Nephrology : JASN》2021,32(4):972
68.
Ennio Polilli Giustino Parruti Francesca D'Arcangelo Elisa Tracanna Luigi Clerico Vincenzo Savini Francesco D'Antonio Maurizio Rosati Lamberto Manzoli Domenico D'Antonio Giovanni Nigro 《Clinical and Vaccine Immunology : CVI》2012,19(12):1991-1993
Hyperimmune globulins were reported to prevent and treat fetal cytomegalovirus (CMV) infection during pregnancy. Here, we report that infusions of standard human intravenous immunoglobulin significantly increase CMV IgG titers and avidity indexes in pregnant women, paving the way to their use for passive transfer of maternal CMV humoral immunity to fetuses. Preliminary data on perinatal outcomes of the first 67 newborns are encouraging. 相似文献
69.
70.